The U.S. home infusion therapy industry is a $19 billion market serving more than 3.2 million patients every year, according to the National Home Infusion Association (NHIA). Market analysts project growth rates between 7.3% and 8.9% annually through 2034, with the U.S. market alone expected to reach somewhere between $31 billion and $43 billion within the decade. The demand drivers have never been more aligned: an aging population, rising chronic disease burden, payer incentives pushing care out of hospitals, and a growing pipeline of biologic drugs that require professional infusion services.
But underneath the growth projections is a constraint that doesn't get nearly enough attention: there aren't enough qualified nurses to deliver the care.
This isn't a staffing inconvenience. It's a structural bottleneck—one that threatens to limit patient access, stall market expansion, and widen care gaps across the country. Here's why, and what the industry needs to do about it.
The Market Is Ready. The Pipeline Is Growing.
NHIA's March 2026 Infusion Industry Trends Report—based on three years of claims data—confirms that home and alternate site infusion is expanding across all five major therapy categories: anti-infectives, home enteral nutrition, parenteral nutrition, specialty infusion, and immune globulin. The report also documents how Medicare coverage remains fragmented and incomplete, a policy limitation that simultaneously constrains current access and represents significant latent demand.
Less discussed but equally important is what's happening upstream in the pharmaceutical pipeline. The Inflation Reduction Act (IRA) created what the industry calls the "pill penalty"—small molecule drugs become eligible for Medicare price negotiation after nine years, while biologic drugs are protected for 13. That four-year gap has prompted a measurable shift in R&D investment toward biologics. As Bourne Partners noted in their December 2025 infusion therapy analysis, the IRA has driven a pivot toward biologic drug development, many of which will require infusion.
More biologics in the pipeline means more infusion demand. More infusion demand means more nurses. And that's where the math starts to break down.
The Nursing Shortage in Numbers
The workforce challenge in home infusion doesn't exist in isolation. It's layered on top of a nationwide nursing shortage that, despite post-pandemic recovery efforts, remains structurally entrenched.
8.06% — The projected national nursing shortage rate for 2026, meaning supply meets only about 92% of demand (HRSA, 2025).
17.6% — National RN turnover rate for 2025, up 1.2 points from the prior year—reversing post-pandemic improvements (NSI, 2026).
80,162 — Qualified applications turned away from U.S. nursing programs in 2024, up from 65,766 the year before (AACN, 2025).
138,000+ — Nurses who have exited the workforce since 2022, with nearly 40% of those still practicing expressing intent to leave by 2029 (NCSBN).
The latest HRSA workforce projections, released in December 2025, estimate that the U.S. will face persistent RN shortages through at least 2038. These gaps are not evenly distributed—nonmetropolitan areas face projected shortages exceeding 11%, compared to roughly 2% in metro areas.
Meanwhile, turnover is actually getting worse. The 2026 NSI National Health Care Retention & RN Staffing Report, based on data from 527 hospitals covering more than 262,000 registered nurses, found that RN turnover climbed to 17.6% in calendar year 2025. Hospital-wide turnover hit 18.5%. And the report flagged an emerging pattern: RN retirement is increasingly cited as the primary reason nurses voluntarily leave their positions.
The Education Pipeline Can't Keep Up
The problem isn't lack of interest in nursing. BSN program enrollment actually increased 4.9% in 2024, according to AACN data. The bottleneck is institutional capacity. Over 80,000 qualified applications to nursing programs were turned away last year, primarily due to faculty shortages, limited clinical placement sites, and budget constraints.
The cycle is self-reinforcing: not enough faculty means not enough nursing school seats, which means not enough new nurses, which means not enough experienced nurses to eventually become faculty. In 2024, nursing schools reported 1,588 full-time faculty vacancies, and more than a third of current faculty are expected to retire within the coming years. A bipartisan bill introduced in 2026—the Nurse Faculty Shortage Reduction Act—would create a federal program to supplement educator salaries, but it's still working its way through committee.
Home Infusion Has a Compounding Problem
If the general nursing shortage creates the foundation, home infusion's specialized requirements create the compounding effect.
A 2024 study published in the Infusion Journal—the first peer-reviewed descriptive workforce assessment of home infusion nurses—surveyed 524 nurses nationally and painted a detailed picture of who these clinicians are.
Mean age: 50 years old. The workforce is experienced but aging.
95%+ have 6 or more years of total nursing experience before entering home infusion.
Most common backgrounds: Medical-surgical (49.6%), ICU (34.5%), Emergency (26.0%).
Education: 53% hold a BSN, 32% hold an ADN.
Source: Haines, Counce, & Charron (2024), Infusion Journal, 3(2).
The takeaway is straightforward: you can't recruit just any available RN into home infusion. The field requires experienced clinicians with years of acute care training who are willing to transition into an autonomous, home-based practice model. Infusion therapy and vascular access are not part of standard nursing school curricula—these skills are learned on the job. And the pool of nurses who fit this profile is shrinking as the broader workforce ages and hospitals compete aggressively to retain their own experienced staff.
The Retention Advantage Nobody Talks About
Here's the counterpoint that doesn't get enough attention: home infusion retains nurses at dramatically higher rates than nearly every other care setting.
The NHIA workforce study found that only 15.84% of home infusion nurses plan to leave the field within five years—and 65% of those cite retirement, not burnout or dissatisfaction. Compare that to hospital RN turnover at 17.6% annually, or the home health agency sector broadly, where annual turnover approaches a staggering 79.2%.
That contrast matters. Home infusion nurses stay because the practice setting offers something structurally different: genuine clinical autonomy, manageable patient ratios, the ability to build long-term patient relationships, and work that is both specialized and meaningful. The industry's problem isn't keeping nurses once they arrive. It's getting them through the door in the first place.
Policy Is About to Make This Harder
The legislative landscape in 2026 adds another dimension to the workforce equation—and it's one that should concern anyone thinking about industry capacity.
In February 2026, the Joe Fiandra Access to Home Infusion Act was signed into law, expanding Medicare's qualifying criteria for certain home-infused drugs. It's a meaningful step. But the bigger piece of legislation is still moving through Congress: the Preserving Patient Access to Home Infusion Act (H.R. 2172 / S. 1058), which has strong bipartisan support in both chambers.
If passed, this bill would establish Medicare coverage for the full scope of professional services that make home infusion possible, remove the physical-presence requirements that have limited provider participation, and expand access to IV anti-infective treatments. Industry estimates suggest this could open access for as many as one million additional Medicare beneficiaries annually.
From a workforce perspective, the math is simple: if Medicare access expands—which it appears likely to do—demand for qualified home infusion nurses will spike at precisely the moment when supply is most constrained. Every new patient approved for home infusion requires a nurse to administer the first dose, monitor for adverse reactions, educate the patient, and manage the vascular access device. Legislative access without clinical capacity is, functionally, no access at all.
What This Means for Patients
When qualified infusion nurses aren't available, patients approved for home infusion face delays in therapy initiation. For patients receiving immune globulin therapy—particularly those with primary immunodeficiency disorders or chronic inflammatory demyelinating polyneuropathy (CIDP)—those delays carry real clinical consequences. Gaps in therapy can increase infection risk, trigger disease relapses, and contribute to progressive neurological decline.
The shift toward home-based biologics and specialty infusion is accelerating exactly when the nurse supply is tightest. Home infusion is proven to reduce hospitalization rates, lower nosocomial infection risk, and improve patient satisfaction and adherence. But the system can't realize these benefits if the workforce to deliver the care doesn't exist.
What's emerging is a care access gap—not driven by insurance coverage or drug availability, but by the absence of the clinical infrastructure needed to deliver therapy safely in the home. And it disproportionately affects patients in nonmetropolitan areas, where HRSA projects the steepest nursing shortages.
What the Industry Needs to Do
There's no single fix for a bottleneck this structural. But there are levers the industry can pull—some already being tested, others overdue.
Build Scalable Onboarding Pathways
Since infusion therapy isn't part of standard nursing education, the industry needs structured programs that can transition experienced acute care nurses into home infusion efficiently and safely. Multi-phase onboarding models—combining credentialing, didactic education, and supervised joint visits with experienced preceptors—reduce the burden on specialty pharmacies while producing nurses who are prepared for autonomous practice from day one. These programs are emerging, and they need to scale.
Rethink the Staffing Model
Specialty pharmacies increasingly face a build-versus-outsource decision on their nursing workforce. For mid-market and smaller pharmacies without dedicated recruitment infrastructure, supplemental nursing agencies that specialize in home infusion offer a scalable alternative to in-house staffing. These agencies maintain pre-credentialed, pre-trained pools of experienced infusion nurses who can be deployed directly into pharmacy-directed patient homes—decoupling a pharmacy's patient volume capacity from its ability to recruit nurses independently. As the market grows, this model may prove to be the most practical near-term mechanism for closing the demand-supply gap.
Leverage the Retention Advantage
The data from the NHIA workforce study shows that home infusion has a structural retention advantage that the industry hasn't fully leveraged in its recruitment messaging. Hospital RN turnover sits at 17.6% annually. Home health turnover approaches 79%. Home infusion nurses, meanwhile, overwhelmingly stay. Recruitment campaigns that position home infusion as a deliberate career destination—not a fallback from burnout—are more likely to attract the experienced clinicians the field needs.
Connect Policy Reform to Workforce Investment
Passage of the Preserving Patient Access to Home Infusion Act would be a significant win for patient access. But legislative reform without corresponding investment in workforce development risks creating a wider care gap than the one that exists today. The industry and its advocates should push for targeted incentives—loan repayment programs for nurses who commit to home infusion, funding for infusion-specific clinical training, and better alignment between access expansion and workforce pipeline development.
The Bottom Line
The home infusion market is on a trajectory that nearly every indicator supports. The drugs are ready. The payers are increasingly aligned. The legislation is moving. And patients overwhelmingly prefer to receive care at home.
But all of it depends on one operational reality: there must be enough qualified nurses to deliver the care.
The national nursing shortage, the specialized requirements of infusion practice, the aging of the current workforce, and the constrained education pipeline collectively create a bottleneck that market forces alone won't resolve. Addressing it requires coordinated investment in nurse education, scalable onboarding and staffing models, recruitment strategies that leverage the field's proven retention advantage, and policy reform that links access expansion to workforce development.
The home infusion industry's growth trajectory doesn't depend on whether demand will continue to rise—it will. It depends on whether the industry can build the clinical workforce to meet it.
Sources
- American Association of Colleges of Nursing. (2024). 2023–2024 Enrollment and Graduations in Baccalaureate and Graduate Programs in Nursing.
- American Association of Colleges of Nursing. (2025). Schools of nursing see enrollment increases across most program levels [Press release]. AACN.
- American Association of Colleges of Nursing. (2026). Nursing Faculty Shortage Fact Sheet. AACN.
- Bourne Partners. (2025). Perspectives and Research into Recent Trends: Infusion Therapy Report.
- Global Market Insights. (2025). U.S. Home Infusion Therapy Market Size & Analysis, 2034.
- Haines, D., Counce, J., & Charron, J. (2024). Association between years of nursing experience and clinical background among home infusion nurses. Infusion Journal, 3(2), 5–11.
- Health Resources and Services Administration. (2025). Nurse Workforce Projections, 2023–2038. Bureau of Health Workforce.
- National Home Infusion Association. (2026). Infusion Industry Trends Report. NHIA.
- National Home Infusion Association. (2026). Congress takes steps toward expanding home infusion access [Press release]. NHIA.
- Nightingale College. (2026). Nursing shortage: 2026 US statistics & key insights.
- NSI Nursing Solutions. (2026). 2026 NSI National Health Care Retention & RN Staffing Report.
- Nurse.org. (2026). Nurse Faculty Shortage Reduction Act aims to address major nursing education bottleneck.
- Precedence Research. (2025). Home Infusion Therapy Market Size to Hit USD 84.6 Bn by 2034.
- Straits Research. (2026). Home Infusion Therapy Market Size, Share & Growth Graph by 2034.